IncellDx signs liquid biopsy distribution agreement with Singapore-based Biolidics

IncellDx and Biolidics have announced that they have signed a distribution agreement for the IncellDx bioINK® PD-L1 CTC Core Kit. Biolidics will distribute the product with the Biolidics’ ClearCell® FX1 System.

The IncellDx bioINK® PD-L1 Core Kit is pre-optimized to enable highly sensitive and specific quantification of protein or mRNA expression on CTCs at a single-cell-by-cell resolution for microfluidic chips. The IncellDx proprietary fixation method minimizes clumping and aggregates of platelets and red blood cells. Further, the bioINK® preserves RNA and DNA for downstream sequencing applications following pre-identification of CTCs.

We are very excited to expand our launch of our proprietary, optimized Liquid Biopsy reagent technology contained in our bioINK® kits. This agreement covers the first of many cancer specific bioINK® kits including kits for breast cancer, lung cancer, urologic cancers, and sarcomas. In addition, we have designed the detection system for enumeration in such a way that does not eliminate the ability to perform downstream single cell sequencing for research,” added Bruce Patterson CEO of IncellDx.